Medication info
Dapagliflozin/Metformin Extended-Release Tablets 10/1000 mg

Dapagliflozin/Metformin Extended-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Yellow, bilaterally convex, oval extended-release film-coated tablets
Packaging
30 tablets/box [(6 tablets/PTP*5)], 200 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202300146 · Approved 2023.01.06 · Insurance code 665003280

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular diseases
  • cardiovascular risk factors.
View approved original text

This drug is used to effectively improve blood sugar control in adult patients with Type 2 diabetes when used in combination with a dietary regimen and exercise therapy. It can particularly help prevent cardiovascular events in patients with cardiovascular diseases or risk factors, so it is important to take it carefully under the guidance of professionals. This drug assists in blood sugar control in the management of Type 2 diabetes and contributes to improving patient health.

How to take

Adult dose

The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medicine can cause a rare side effect known as severe lactic acidosis, so it should not be used in patients with impaired kidney function or conditions such as severe infections, dehydration, or acute myocardial infarction. Additionally, caution is required when used in conjunction with other diabetes medications such as insulin or sulfonylureas due to the risk of hypoglycemia. Patients with moderate to severe kidney impairment or the elderly must evaluate kidney function and fluid status before administering this drug and continue monitoring during treatment. This drug may increase the risk of genital and urinary tract infections, so if infection symptoms appear, medical consultation should be sought immediately. Women who are pregnant or breastfeeding should not use this drug, and women of childbearing potential should confirm their pregnancy status before taking it. Excessive alcohol consumption may increase the risk of side effects from this drug, so it is advisable to avoid it. Since this medicine can affect blood sugar control, dosage adjustments may be necessary when used in combination with other medications due to potential interactions. If symptoms of hypoglycemia or dehydration occur, medical personnel should be informed immediately, with extra caution advised for elderly patients or those with impaired kidney function. Regular blood tests and kidney function tests should be performed during the use of this drug, and it is advisable to monitor vitamin B12 levels as well. If surgery or imaging tests are scheduled, this drug should be temporarily discontinued, and resumption should occur only after confirming normal kidney function post-examination. Finally, safety and effectiveness in children have not been established, so it should not be administered to children, and it should be kept out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • pain during urination
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepticemia
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumors
  • lung malignancies
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • benign prostatic hyperplasia
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also advisable to store it at room temperature, which should not be too cold or too hot, ideally between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, bilaterally convex, oval extended-release film-coated tablets

Package unit

30 tablets/box [(6 tablets/PTP*5)], 200 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.